Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer

European Journal of Cancer

Volumn 36, Issue 1, 2000, Pages 68-73

  Seki, N ^a   Kodama, J ^a   Hongo, A ^a   Miyagi, Y ^a   Yoshinouchi, M ^a   Kudo, T ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Angiogenesis; Endometrial cancer; Platelet derived endothelial cell growth factor; RT PCR; Vascular endothelial growth factor

Indexed keywords

PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CLINICAL FEATURE; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ENDOMETRIAL NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MICROCIRCULATION; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033985876     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00201-4     Document Type: Article

References (41)

1. Berek J.S., Adashi E.Y., Hillard P.A. Novaks Gynecology. 1996;Williams and Wilkins, Maryland. 1073-1077.
2. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 267:1992;10931-10934.
3. Folkman J. What is the evidence that tumors are angiogenesis-dependent? J. Natl. Cancer Inst. 82:1990;4-6.
4. Liotta L., Kleinerman J., Saldel G. Quantitative relationships of intravascular tumor cells, tumor vessel, and pulmonary metastases following tumor implantation. Cancer Res. 34:1974;997-1004.
5. Salvesen H.B., Iversen O.E., Akslen L.A. Independent prognostic important of microvessel density in endometrial carcinoma. Br. J. Cancer. 77:1998;1140-1144.
6. Kirschner C.V., Alanis-Amezcua J.M., Martin V.G.et al. Angiogenesis factor in endometrial carcinoma. a new prognostic indicator? Am. J. Obstet. Gynecol. 174:1996;1879-1882.
7. Wagatsuma S., Konno R., Sato S., Yajima A. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer. 82:1998;520-530.
8. Kaku T., Kamura T., Kinukawa N.et al. Angiogenesis in endometrial carcinoma. Cancer. 80:1997;741-747.
9. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:1989;851-858.
10. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secret a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
11. Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrin. Rev. 13:1992;18-32.
12. Ferrara N., Leung D.W., Cachianes G., Winer J., Henzel W.J. Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells. Meth. Enzymol. 198:1991;391-405.
13. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5:1991;1806-1814.
14. Yeo T., Senger D., Dvorak H., Freter L., Yeo K. Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor). Biochem. Biophys. Res. Commun. 3:1991;1568-1575.
15. Ishikawa F., Miyazono K., Hellman U.et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 338:1989;557-562.
16. Furukawa T., Yoshimura A., Sumizawa T.et al. Angiogenic factor. Nature. 356:1992;668.
17. Sumizawa T., Furukawa T., Haraguch M.et al. Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J. Biochem. 114:1993;9-14.
18. Haraguchi M., Miyadera K., Uemura K.et al. Angiogenic activity of enzymes. Nature. 368:1994;198.
19. Miyadera K., Sumizawa T., Haraguchi M.et al. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 55:1995;1587-1590.
20. FIGO news. Int J Gynecol Obstet 1989, 28, 189-193.
21. Mimori K., Mori M., Shiraishi T., Haraguchi M., Ueo H., Akiyoshi T. Clinical significance of pyrimidine nucleoside phosphorylase in colorectal carcinoma. Int. J. Oncol. 10:1997;493-496.
22. Fujita N., Yaegashi N., Ide Y.et al. Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res. 54:1994;3922-3928.
23. Kodama J., Seki N., Tokumo K.et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur. J. Cancer. 35:1999;485-489.
24. Kodama J., Seki N., Tokumo Ket al. Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer. Oncol. Rep. 6:1999;619-620.
25. Kodama J., Hayase R., Okuda H., Yoshinouchi M., Kudo T. Reverse correlation between P-glycoprotein expression and proliferative activity in endometrial adenocarcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 59:1995;45-51.
26. Folkman J., Klagsburn M. Angiogenic factors. Science. 235:1987;442-447.
27. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1991;1-8.
28. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
29. Kuwano M., Ushiro S., Ryuto M.et al. Regulation of angiogenesis by growth factors. Gann Monogr. Cancer Res. 42:1994;113-125.
30. Ishikawa F., Miyazono K., Hellman U.et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial growth factor. Nature. 338:1989;557-562.
31. Shifren J.A., Tseng J.F., Zaloudek C.J.et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J. Clin. Endocrinol. Metabol. 81:1996;3112-3118.
32. Fujimoto J., Ichigo S., Sakaguchi H., Hirose R., Tamaya T. Expression of platelet-derived endothelial cell growth factor and its mRNA in uterine endometrium during the menstrual cycle. Mol. Hum. Reprod. 4:1998;509-513.
33. Guidi A.J., Abu-Jawdeh G., Tognazzi K., Dvorak H.F., Brown L.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer. 78:1996;454-460.
34. Wilson T.O., Podratz K.C., Gaffey T.A., Malkasian G.D.J., O'Brien P.C., Naessens J.M. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am. J. Obstet. Gynecol. 162:1990;418-426.
35. Fanning J., Evans M.C., Peters A.J., Samuel M., Harmon E.R., Bates J.S. Endometrial adenocarcinoma histologic subtypes. clinical and pathologic profile Gynecol. Oncol. 32:1989;288-291.
36. Fujimoto J., Ichigo S., Sakaguchi H., Hirose R., Tamaya T. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers. Cancer Lett. 130:1998;115-120.
37. Fujiwaki R., Hata K., Iida K., Koike M., Miyazaki K. Immunohistochemical expression of thymidine phosphorylase in human endometrial cancer. Gynecol. Oncol. 68:1998;247-252.
38. Nicosis R.F. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis. Am. J. Pathol. 153:1998;11-16.
39. Asano M., Yukita A., Matsumoto T., Kondo S., Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res. 55:1995;5296-5301.
40. Miwa M., Nishimura J., Kamiyama T., Ishitsuka H. Conversion of 5′-deoxyfluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients. Jpn. J. Cancer Chemother. 14:1987;2924-2929.
41. Schueller J., Cassidy J., Reigner B.G.et al. Tumor selectivity of XELODATM in colorectal cancer patients. Proc. Am. Soc. Clin. Oncol. 16:1997;227a.